The figures that matter most, each traceable to one entry and one named source.
Standing rule: no scores. Color marks whether something is in force, reversed, contested, concluded, or permanent, not good or bad.
Unscored · 97 entries · last change 2026-08-16
New here? Read this first (30 seconds)
Color is a legal fact, not an opinion. It shows (whether something is still in force, was reversed, or is contested in court), never whether it was good or bad.
Every number links to its source and to how strongly it can be tied to the action (). Click any figure to see the full evidence.
Nothing here is scored, graded, or ranked. When two credible sources disagree, this archive shows both numbers instead of picking one.
Wins are in here too. See or filter the Ledger by .
Nobody is asking you to trust a byline. There isn’t one — the archive is anonymous, on purpose, which is exactly why it has to be checkable without one. See and check one entry against its own source yourself.
Public approval37% approve · 57% disapproveNet approval of roughly −21 is the lowest of either term, below his post-January-6 floor of −19. Independent approval near 34%.Polling averages, early August 2026
Next scheduled testMidterm elections, November 2026Three months out. Independent approval below the level that preceded the 2018 wave; the entire House and a third of the Senate are on the ballot.Election calendar
Figures of record
▲ and ▼ are direction. Color is measured : who paid, who gained, not whether that was right. Click a figure that has an entry. Not every figure here is a cost. Filter to just .
▲$2.8T
added to the national debt so far this term
18 months in; the JEC reported $2.77T year-over-year in April 2026
Net cost
Added since January 2025 — from $36.22T to roughly $39T. Borne by future taxpayers through debt service; sources put the range at $2.2T–$2.8T depending on cut-off.
Gross national debt · Treasury / Federal Reserve
▲54
more federal judges confirmed this term
On top of 234 in the first term
Transfer
9 appellate, 45 district. Ahead of the 2018 confirmation pace but with a far thinner pipeline — 60 nominees submitted against 137 by this date in 2018.
Lifetime judgeships filled this term · Senate confirmation record
▲369K
total jobs added, Jan 2025 – Mar 2026
vs. 1,565,000 in the final 14 months prior
Transfer
Positive but roughly a quarter the pace of the preceding 14 months. Private sector +609K, offset by federal cuts.
Total nonfarm employment · BLS via FactCheck.org
What this archive is made of
97 entries, 203 effect claims, 520 sourced estimates, 230 linked documents. Zero scores, grades, or rankings.
Where every entry stands today
Color here is a legal and operational fact, not an opinion: whether the action is still in force, was reversed or never fulfilled, is contested in court, has concluded, or is irreversible.
Coverage by domain
Bar segments show the standing mix inside each domain. Click any row to open it in the ledger.
The honesty check on the whole archive. If nearly everything claimed Direct, the archive would be overreaching. Amber marks claims where credible sources reach incompatible conclusions.
Direct138
Contributory28
Contextual20
Disputed17
What the evidence is made of
Every estimate in the archive, grouped by the kind of institution that produced it. Advocacy sources are admissible but never appear alone.
Primary document157
Government data79
Party to the action67
Academic / peer-reviewed52
Nonpartisan scorekeeper41
Advocacy — labeled31
Journalistic verification26
Named / interested parties24
Archive reasoning — not a source17
Cross-ideological convergence13
Mixed / other11
Polling aggregate2
The disagreement, charted
These are the numbers people argue with. Each bar is one published estimate at its own value, never averaged into a single figure, because the width of the gap is itself the finding.
10-year deficit effect — OBBBA
$ trillions, 2025–2034
CBO, excl. interest3.4
CBO, incl. interest4.1
CBO, dynamic (thru 2035)4.7
CRFB, if made permanent5.5
10-year deficit effect — TCJA
$ trillions
JCT, dynamic1.07
JCT, conventional1.46
CBO, incl. interest1.9
Project 2025 implementation — competing trackers
% of that tracker’s own agenda list
CPR / GFI — 532 proposals, method published53
Crowdsourced tracker — 317 objectives, no method48
Employment effect — steel & aluminum tariffs
jobs
Steel production jobs added1000
Steel-consuming mfg. jobs lost-75000
2025-05-12 · Healthcare · initiative
Most-favored-nation drug pricing
76 of 97
Layer 1 — Action
Executive order signed May 12, 2025, directing HHS to pursue most-favored-nation pricing; a similar 2020 rule had been enjoined and later withdrawn.
An executive action directing that Americans not pay more for prescription drugs than the lowest price paid by comparable developed nations.
Layer 2 —
Partially implemented through negotiated agreements
A prior 2020 MFN rule was blocked by courts on procedural grounds and rescinded in 2021. The 2025 effort has proceeded largely through voluntary manufacturer agreements rather than rulemaking, which reduces legal exposure and also reduces enforceability.
Verified as of August 2026
This policy is opposed by parts of the President’s own coalition on free-market grounds and supported by parts of the opposition. Coalition alignment is a poor guide to its merits.
Layer 3 — Measured effects
US drug prices are substantially higher than in peer countries.
US prices average roughly 2-3 times those in other high-income countries across brand drugs.
RAND Corporation comparative pricing studies
Nonpartisan research institute
The gap is a longstanding structural feature predating any recent administration.
Health economics literature
Academic / peer-reviewed
Effect of the policy on prices actually paid.
Voluntary agreements produced announced reductions on specific products; independent verification of net effect on patient out-of-pocket costs is limited.
Announcements and follow-up reporting
Journalistic verification
Manufacturers warn that reference pricing reduces research investment; the size of that effect is contested in the literature.
Industry analyses and academic rebuttals
Industry — interested parties, and academic critique